Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk?

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages 254-264

  Isenor, Jennifer E ^a   Ensom, Mary H H ^b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

25(OH)D; 25 hydroxyvitamin D; Cholecalciferol; Elderly; Geriatrics; Therapeutic drug monitoring; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PLACEBO; VITAMIN D;

ALGORITHM; BONE DENSITY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE MARKER; DRUG MONITORING; FRACTURE; GENETIC DIFFERENCE; HIP FRACTURE; HUMAN; KIDNEY DYSFUNCTION; OBESITY; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

25-HYDROXYVITAMIN D 2; ALGORITHMS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BONE AND BONES; BONE DENSITY; CALCIFEDIOL; CALCIUM; DECISION MAKING; DIETARY SUPPLEMENTS; DRUG MONITORING; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77649212747     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.254     Document Type: Review

References (69)

1. Norman AW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998;67:1108-10.
2. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4-8.
3. Health Canada. Food and nutrition. Available from http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/context/evidfond/vita-d-eng.php. Accessed March 29, 2009.
4. Reginster JY. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin 2005;21:579-86.
5. Hart GR, Furniss JL, Laurie D, Durham SK. Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab 2006;52:335-43.
6. Boonen S, Aerssens J, Dequeker J. Age-related endocrine deficiencies and fractures of the proximal femur. II. Implications of vitamin D deficiency in the elderly. J Endocrinol 1996;149:13-17.
7. Lips P, van Ginkel FC, Jongen MJ, Rubertus F, van der Vijgh WJ, Netelenbos JC. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. Am J Clin Nutr 1987;46:1005-10.
8. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477-501.
9. Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK. HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem 2006;52:1120-6.
10. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990;120(suppl 11):1464-9.
11. Heaney RP. Vitamin D: how much do we need, and how much is too much? Osteoporos Int 2000;11:553-5.
12. Bolland MJ, Grey AB, Ames RW, et al. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 2007;86:959-64.
13. Semba RD, Garrett E, Johnson BA, Guralnik JM, Fried LP. Vitamin D deficiency among older women with and without disability. Am J Clin Nutr 2000;72:1529-34.
14. Elliott ME, Binkley NC, Carnes M, et al. Fracture risks for women in long-term care: high prevalence of calcaneal osteoporosis and hypovitaminosis D. Pharmacotherapy 2003;23:702-10.
15. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33.
16. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 2004;15:87-94.
17. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64.
18. Levi N. Early mortality after cervical hip fractures. Injury 1996;27:565-7.
19. Campbell AJ, Robertson MC. Implementation of multifactorial interventions for fall and fracture prevention. Age Ageing 2006;35(suppl 2):ii60-4.
20. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med 2009;122:793-802.
21. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials [online exclusive article]. Br Med J 2009;339:b3692. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2755728/pdf/bmj.b3692.pdf.
22. Pieper CF, Colon-Emeric C, Caminis J, et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother 2007;5:335-40.
23. Bischoff-Ferrari HA, Can U, Staehelin HB, et al. Severe vitamin D deficiency in Swiss hip fracture patients. Bone 2008;42:597-602.
24. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal U.S. women with acute hip fracture. JAMA 1999;281:1505-11.
25. Gallacher SJ, McQuillian C, Harkness M, Finlay F, Gallagher AP, Dixon T. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin 2005;21:1355-61.
26. Bakhtiyarova S, Lesnyak O, Kyznesova N, Blankenstein MA, Lips P. Vitamin D status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. Osteoporos Int 2006;17:441-6.
27. Moniz C, Dew T, Dixon T. Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin 2005;21:1891-4.
28. Looker AC, Mussolino ME. Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 2008;23:143-50.
29. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008;149:242-50.
30. Dahl E. Mortality and life expectancy after hip fractures. Acta Orthop Scand 1980;51:163-70.
31. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34:265-79.
32. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 2006;81:662-72.
33. International Osteoporosis Foundation. About osteoporosis. Available from www.iofbonehealth.org. Accessed March 29, 2009.
34. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005;(3):CD000227.
35. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.
36. Izaks GJ. Fracture prevention with vitamin D supplementation: considering the inconsistent results [online exclusive article]. BMC Musculoskelet Disord 2007;8:26. Available from http://www.biomedcentral.com/ 1471-2474/8/26.
37. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257-64.
38. Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age Ageing 2006;35:482-6.
39. Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int 2007;18:811-18.
40. Tang BMP, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66.
41. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61.
42. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
43. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-34.
44. Carter GD, Carter CR, Gunter E, et al. Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 2004;89-90:467-71.
45. 3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem 2006;43:23-30.
46. Vieth R. Problems with direct 25-hydroxyvitamin D assays, and the target amount of vitamin D nutrition desirable for patients with osteoporosis. Osteoporos Int 2000;11:635-6.
47. 3 using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency. Am J Clin Pathol 2006;125:914-20.
48. The DEQAS. Vitamin D external quality assessment scheme. Available from www.deqas.org. Accessed March 29, 2009.
49. National Institute of Standards and Technology (NIST) Chemical Science and Technology Laboratory. NIST releases vitamin D standard reference material. Available from http://www.nist.gov/cstl/analytical/vitamind-071409. cfm. Accessed August 7, 2009.
50. 3 and calcium for secondary prevention of low-trauma fractures in elderly people: randomised evaluation of calcium or vitamin D (RECORD) - a randomised placebo-controlled trial. Lancet 2005;365:1621-8.
51. Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women: the OFELY study. Bone 2007;40:716-22.
52. Roddam AW, Neale R, Appleby P, Allen NE, Tipper S, Key TJ. Association between plasma 25-hydroxyvitamin D levels and fracture risk: the EPIC-Oxford study. Am J Epidemiol 2007;166:1327-36.
53. van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, Lips P. Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 2008;42:260-6.
54. Leslie WD, Metge C. Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 2003;6:275-82.
55. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE, Falconer G, Green CL. Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. Am J Clin Nutr 1995;61:1140-5.
56. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995;80:1052-8.
57. Collins D, Jasani C, Fogelman I, Swaminathan R. Vitamin D and bone mineral density. Osteoporos Int 1998;8:110-14.
58. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004;116:634-9.
59. Hunter D, Major P, Arden N, et al. A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J Bone Miner Res 2000;15:2276-83.
60. McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int 1998;8(suppl 2):S3-6.
61. van der Wielen RP, Lowik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995;346:207-10.
62. National Institutes of Health. Dietary supplement fact sheet: vitamin D. Available from http://ods.od.nih.gov/factsheets/VitaminD-pf.asp. Accessed July 30, 2009.
63. Graafmans WC, Lips P, Ooms ME, van Leeuwen JP, Pols HA, Uitterlinden AG. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997;12:1241-5.
64. Glendenning P, Noble JM, Taranto M, et al. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 2003;40:546-51.
65. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ, for the Nottingham Neck of Femur (NONOF) Study Investigators. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham neck of femur (NONOF) study. Age Ageing 2004;33:45-51.
66. Hirani V, Primatesta P. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. Age Ageing 2005;34:485-91.
67. Jacques PF, Felson DT, Tucker KL, et al. Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr 1997;66:929-36.
68. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int 1998;8:222-30.
69. Calgary Health Region. Calcium and vitamin D. Available from http://www.calgaryhealthregion.ca/clin/cme/ccmed/ccform/HCD11- CalciumandVitaminD.pdf. Accessed March 2, 2008.